MEDP — Medpace Holdings, Inc.

Medpace (MEDP) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $706.6 million, a year-over-year increase of 26.5% (25.8% on a constant currency basis).
• Net Income: $123.9 million, up 8.1% from $114.6 million in Q1 2025.
• EBITDA: $149.4 million, a 25.9% increase compared to $118.6 million in the prior year.
• EBITDA Margin: 21.1%, slightly down from 21.2% year-over-year.
• Net Book-to-Bill Ratio: 0.88, indicating net new business awards of $618.4 million, which is below Q4 levels but above Q1 2025.
• Backlog: Approximately $2.9 billion, up 2.9% year-over-year, with an expected $1.94 billion to convert to revenue in the next 12 months.
• Cash Flow from Operating Activities: $151.8 million.
• Cash Position: $652.7 million as of March 31, 2026.

2. Strategic Updates and Business Highlights

• The company acknowledged the departure of President Jesse Geiger after 18.5 years of service.
• Medpace is focusing on expanding its pipeline and improving its win rate through various initiatives.
• The quality of opportunity flow remains strong, despite an increase in cancellations, which are attributed to project-specific issues rather than macroeconomic factors.
• The company continues to hire, indicating confidence in future growth despite recent challenges.

3. Forward Guidance and Outlook

• Medpace reaffirmed its 2026 guidance for revenue, EBITDA, net income, and EPS, maintaining an effective tax rate of 19% to 20% and interest income of $27.5 million.
• The company expects to convert approximately $1.94 billion of its backlog into revenue within the next year.

4. Bad News, Challenges, or Points of Concern

• Cancellations: The company reported the highest cancellation rate in over a year, impacting the net book-to-bill ratio and overall revenue visibility.
• Competitive Pressures: There are concerns about increasing competition in the biotech sector, particularly regarding RFP trends and the impact of large pharma acquisitions on ongoing projects.
• Market Dynamics: Although the company sees good quality opportunities, the decline in RFPs and the competitive landscape may pose challenges moving forward.
• Revenue Growth: Sequential revenue growth is in question, with potential risks from high cancellation rates and a lack of growth in backlog coverage beyond one year.

5. Notable Q&A Insights

• Cancellations: Management clarified that cancellations were primarily project-specific and not driven by financial constraints. Oncology and cardiovascular areas were noted as having higher cancellation rates.
• Impact of M&A: Acquisitions in the biotech space do not typically drive cancellations, but they can limit future opportunities for Medpace.
• AI Investments: Management believes that while AI has potential, it will require significant investment before yielding net benefits.
• Revenue Recognition: The company explained that bookings are recognized upon the first patient in, and cancellations can occur before this point, impacting backlog.
• Future Visibility: There is uncertainty regarding future revenue growth, with management emphasizing the need for either a reduction in cancellations or an increase in new bookings to stabilize growth.

Overall, while Medpace reported strong year-over-year growth in revenue and EBITDA, the rising cancellation rates and competitive pressures present significant challenges that could impact future performance. The company remains focused on strategic initiatives to enhance its pipeline and win rate, maintaining a cautious yet optimistic outlook for the remainder of 2026.